Clinical trial · Observational
Follow-up in Gynecological Cancer Survivors
Follow-up in Gynecological Cancer Survivors: An EORTC QLG-GCG Survivorship Study
NCT03515993CI-TRIAL-00111225active not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A cross-sectional prospective study of follow-up in gynecologic cancer patients after primary treatment
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gynecologic Cancer | Malignant Female Reproductive System Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (5)
- measure
- Health-related quality of life
- timeFrame
- 15 months after first patient inclusion
- description
- It will be evaluated using self-administered EORTC QLQ-C30 questionnaire
- measure
- Health-related quality of life
- timeFrame
- 15 months after first patient inclusion
- description
- It will be evaluated using self-administered questions on anxiety (from the EORTC quality of life item library)
- measure
- Health-related quality of life
- timeFrame
- 15 months after first patient inclusion
- description
- It will be evaluated using self-administered EORTC OUT-PATSAT-C7 questionnaire
- measure
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histological proven gynecological cancer (cervical, endometrial, ovarian (including fallopian tube and peritoneal primary), vulva). * FIGO stage I-IV before completion of primary therapy. * Disease-free without any evidence of relapse: no symptoms or signs potentially indicating recurrent disease (assessed according to standard clinical parameters using physical and gynecological examination, blood tests, CA 125 (ovarian cancer), or radiological imaging techniques). * At least 6 months but no more than 5 years since completion of primary treatment. * Performance status 0, 1 or 2 (WHO scale). * Age ≥ 18 years. * Ability to understand and fill out questionnaires. * Written informed consent according to ICH/GCP, and national/local regulations. Exclusion Criteria: * Other cancer diagnosis in the past 5 years. * Patients participating in interventional clinical studies with Quality of Life as primary endpoint. * Any psychological (including pre-existing psychiatric disorders), familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.
References
Publications (0)
Data not yet available
No reference posted for this study.